Histologically confirmed GBM, Radiotherapy completed with concurrent TMZ at least 12 weeks prior to start of study treatment. Or pathological verification of recurrent tumour at least 4 weeks after radiotherapy with concurrent TMZ. Exclusion of IDH mutants or secondary GBMs. The gene discussed is IDH1; the disease is neoplasm.